Acorda Therapeutics Inc. (ACOR)
Symbol Info
Listed Symbol ACOR
Name Acorda Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $471,433,000
Latest Fiscal EPS $0.71
Price Info
21 Day Moving Average $2.8507
21 Day EMA $2.819370
50 Day Moving Average $3.0577
50 Day EMA $3.512770
200 Day EMA $8.813610
200 Day Moving Average 9.323330
52 Week High $21.63
52 Week Low $2.27
52 Week Change $-87.032196
Alpha -0.037850
Beta 1.2599
Standard Deviation 0.164540
R2 0.069145
Periods 60
Share Information
10 Day Average Volume 1,160,075
20 Day Average Volume 1,220,461
30 Day Average Volume 1,599,604
50 Day Average Volume 1,682,111
Outstanding Shares 48,108,022
Float Shares 47,063,890
Percent Float 97.83%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 409
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 10,057,715
Institute Holdings Percent -
Institute Sold Previous 3 Months 10,518,221
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 7
Insider Holdings Percent 2.20%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,044,132
Price Change
7 Day Price Change $0.0500000
7 Day Percent Change 2.07%
21 Day Price Change $-0.54
21 Day Percent Change -18.00%
30 Day Price Change $-1.0899999
30 Day Percent Change -30.70%
Month To Date Price Change $-0.41
Month To Date Percent -14.29%
90 Day Price Change $-4.43
90 Day Percent Change -64.30%
Quarter To Date $-0.41
Quarter To Date Percent -14.29%
180 Day Price Change $-8.68
180 Day Percent Change -77.92%
200 Day Price Change $-10.95
200 Day Percent Change -81.66%
Year To Date $-13.12
Year To Date Percent -84.21%
Profile
Description Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders.Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.
Details
Issue Type CS
Market Cap $118,345,734
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 48,108,022
CEO Ron Cohen
Employees 474
Last Audit UE
Classification
CIK 0001008848
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 420 Saw Mill River Road
Ardsley, NY 10502
Website http://www.acorda.com
Facisimile +1 914 347-4560
Telephone +1 914 347-4300
Email fvonella@acorda.com
Key Ratios
Profitability
EBIT Margin -27
EBITDA Margin -20.5
Pre-Tax Profit Margin -7.1
Profit Margin Cont -40.1
Gross Margin 78.30
Profit Margin TOT -40.1
Income Statements
Revenue $163,342,000
Revenue Per Share $3.3953
Revenue 3 Years $-18.61
Revenue 5 Years $-3.88
Valuation Measures
PE Ratio -
Enterprise Value $198,370,023
Price To Sales 0.724527
Price To Free Cash -0.8
PE High Last 5 Years -
Price To Book 0.2
Price To Cash Flow 7.4
PE Low Last 5 Years -
Price To Tangible Book -0.9
Financial Strength
Total Debt To Equity 0.7
Int Coverage -3.7
Current Ratio 3.8
Leverage Ratio 2.2
Quick Ratio 3.4
Long Term Debt To Capital 0.39
Assets
Receivables Turnover 1.2
Invoice Turnover 3.40
Assets Turnover 0.10
Management Effectiveness
Return Assets -6.49
Return On Equity -13.79
Return On Capital -7.26
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACOR
Acorda The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.